ImetelChat

You're right.

I found this on the Multiple Myeloma Research Foundation website: Additional Experimental Treatments Phase II Imetelstat (GRN163L) Geron Corporation Telomerase inhibitor that induces apoptosis and inhibits myeloma cell growth; enrollment completed Link: http://www.themmrf.org/multiple-myeloma-knowle...

Bio, I found this on imetelstat DOT info: The Telomerase Inhibitor, Imetelstat, Rapidly Reduces Myeloma Cancer Stem Cells (CSCs) in a Phase II Trial C.A. Huf et al. (2012) MM cells are relatively resistant to a wide range of anti-myeloma agents. In preclinical models, the novel telomerase inhibitor ...

From the article 'Are These 3 Biotechs Destined to Be Bought Out? Are Celator Pharmaceuticals, Geron Corp., and Juno Therapeutics barreling toward a buyout? by George Budwell, Motley Fool, 24 April 2016 The merger and acquisition frenzy that's been spreading across the biotech landscape over the las...

The following text will explain a bit more on the thrombocytopenia issue: Myelosuppression in patients treated with the telomerase inhibitor imetelstat is not mediated through activation of toll-like receptors Toll-like receptors (TLRs) recognize pathogen-associated molecular patterns to trigger inn...

(Ticker Report, 21 April 2016) Morgan Stanley raised its position in shares of Geron Co. (NASDAQ:GERN) by 194.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 268,626 shares of the biopharmaceutical company’s stock after buying an additional 177...

There will be no presentation of preliminary results of IMbark, as that is not aloud for the type of session Tefferi is in. Here are the rules for so called Trials In Progress Sessions (TPS): Per ASCO, the following information is not acceptable in a Trials in Progress abstract: * Any preliminary da...

Examining Two Approaches for Improving the Care of Myelofibrosis CURE spoke with John O. Mascarenhas about advancements in the care of myelofibrosis. BRIELLE URCIUOLI PUBLISHED: APRIL 20, 2016 From the interview: 'There are a number of different novel therapeutic approaches that are being evaluated...

This is what Hoosier thinks about ASCO (posted on SA 20 April 2016): "For the following reasons, I believe Dr. Tefferi is likely presenting the initial IMbark data at the upcoming ASCO conference. 1) Dr. Tefferi's Mayo trial was NOT randomized. 2) Dr. Tefferi's Mayo trial was NOT limited to patients...

I think that the full article of Baerlocher should explain it. For me it is a little too technical.

A repost by sdrawkcabeman (YMB, 20 April 2016) Approval in MF is a given. Approval in MDS is very likely. Time to set your sights on AML. The CRs in MF means certain approval, not just b/c of CRs but also in context of inadequate SOC. The pilot's MDS cohort showed Imet is very active in MDS, makes p...

Btw: Janssen will be exhibitor at this ASCO with two stands:
Janssen Biotech, Inc., booth 18079
Janssen Pharmaceuticals, Inc., booth 18084

Hi Phil, I checked the ASCO program and my observation is that all the presenters are either from hospitals, universities, clinics or other healthcare institutions. So I suppose it is not usual for this conference that pharma's are presenting. At least Tefferi is independent, so that adds credibilit...

Scott, on Yahoo 'InPlay from Briefing.com' the following was published about the two AACR poster presentations: "1. The first poster presentation described results that treating acute myeloid leukemia cell lines with imetelstat enhanced the effects of agents currently used for the treatment of AML. ...

Nice find! Although from March 2015, the article is becoming more actual every day that we are approaching the start of the AML trial this year. For those who don't want to click on links, here is the text: Team Finds New Treatment for Acute Myeloid Leukaemia (AML) Issels, Integrative Immuno-Oncolog...

Bio, I just saw that scott was addressing this question to you...I shot of bit quick. Sorry. Nevertheless I would be interested to hear your opinion on this.

There was a time that Tefferi was a bit explicitly ventilating in public that Jakafi was only palliative and that he was looking for a drug that really takes away the disease. He did that in a period that Jakafi was just approved and everybody was a kind of hyping about the drug. Tefferi is very str...

I found this: A Phase 1 Trial of Imetelstat in Children with Refractory or Recurrent Solid Tumors: A Children’s Oncology Group Phase 1 Consortium Study (ADVL1112) Published online 2013 Oct 4 Purpose Imetelstat is a covalently-lipidated 13-mer thiophosphoramidate oligonucleotide that acts as a potent...

Good post. Is there any documentation to be found about this study?

Sargasso, I think your question is very interesting, but difficult to answer. The two companies are very different, although they seem to serve the same market. Incyte is diversifying on the JAK-inhibitors into Rheumatoid Arthritis (Baricitinib, Phase3 CT), which is a large market and not targeted b...